4LL Stock Chart & Stats
CHF5.21
CHF0.00(0.00%)
At close: 4:00 PM EDT
CHF5.21
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF4.79 - CHF12.00
Previous CloseN/A
Volume0.00
Average Volume (3M)5.00
Market Cap
CHF896.25M
Enterprise ValueCHF1.80B
Total Cash (Recent Filing)CHF774.35M
Total Debt (Recent Filing)CHF1.04B
Price to Earnings (P/E)―
Beta-0.60
Next Earnings
Oct 28, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding181,684,020
10 Day Avg. Volume0
30 Day Avg. Volume5
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.89
Price to Sales (P/S)0.49
P/FCF Ratio4.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF6.37Price Target Upside22.24% Upside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)-0.72
Revenue Forecast (FY)CHF2.01B
Bulls Say, Bears Say
Bulls Say
Positive Cash GenerationStrong positive operating and free cash flow provides Teladoc with internal funding for operations, product investment, and the BetterHelp insurance transition. This cash generation also reduces reliance on external financing while the company works toward sustainable accounting profitability.
Integrated Care Scale And Margin ExpansionIntegrated Care combines a very large member base with improving profitability, suggesting that scale, chronic-care enrollment, and hybrid-care adoption are supporting operating leverage. Continued margin expansion in this core segment can help offset weakness elsewhere and strengthen durable earnings quality.
Platform And Insurance Capability ExpansionInvestment in a unified connected-care platform and AI-driven clinical intelligence broadens Teladoc’s product capabilities, while the insurance rollout expands access to a structurally important payment channel. Together, these initiatives can deepen customer relationships and support longer-term platform relevance.
Bears Say
Persistent Losses And Weak Revenue TrendTeladoc has improved from its larger prior losses but remains below break-even, while declining revenue limits operating leverage and confidence in sustainable earnings power. Continued losses can constrain capital allocation and make future profitability dependent on successful execution and renewed growth.
BetterHelp Revenue ContractionBetterHelp’s declining revenue is a material drag because the segment is undergoing a shift from cash-pay acquisition toward insurance reimbursement. The revised outlook indicates that this transition is affecting the consolidated growth profile and may weigh on results until the new model reaches scale.
Provider Capacity Limits Insurance ConversionThe insurance strategy depends on sufficient providers across states, payers, appointments, and times, but current capacity has lagged demand in several markets. This execution constraint can delay revenue replacement, reduce the benefits of the national rollout, and prolong pressure on BetterHelp performance.
Teladoc News
4LL FAQ
What was Teladoc’s price range in the past 12 months?
Teladoc lowest stock price was CHF4.79 and its highest was CHF12.00 in the past 12 months.
What is Teladoc’s market cap?
Teladoc’s market cap is CHF896.25M.
When is Teladoc’s upcoming earnings report date?
Teladoc’s upcoming earnings report date is Oct 28, 2026 which is in 15 days.
How were Teladoc’s earnings last quarter?
Teladoc released its earnings results on Jul 29, 2026. The company reported -CHF0.175 earnings per share for the quarter, beating the consensus estimate of -CHF0.208 by CHF0.033.
Is Teladoc overvalued?
According to Wall Street analysts Teladoc’s price is currently Undervalued.
Does Teladoc pay dividends?
Teladoc does not currently pay dividends.
What is Teladoc’s EPS estimate?
Teladoc’s EPS estimate is -0.18.
How many shares outstanding does Teladoc have?
Teladoc has 181,684,020 shares outstanding.
What happened to Teladoc’s price movement after its last earnings report?
Teladoc reported an EPS of -CHF0.175 in its last earnings report, beating expectations of -CHF0.208. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Teladoc?
Currently, no hedge funds are holding shares in CH:4LL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teladoc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF6.37 (22.24% Upside)
CHF6.37 (22.24% Upside)
Blogger Sentiment
Bullish
CH:4LL Sentiment 65%
Sector Average 66%
Sector Average 66%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.00%
12-Months-Change
Fundamentals
Return on Equity
-13.08%
Trailing 12-Months
Asset Growth
-4.68%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Teladoc
Teladoc Health, Inc. offers remote medical services to individuals both domestically in the United States and internationally. Their extensive range of solutions covers a wide array of health needs, from routine and acute conditions to complex and long-term illnesses such as diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and various mental health issues. The company delivers numerous programs, including virtual primary and specialized medical care, management for chronic diseases, expert second opinion services, mental wellness support, and core platform and service offerings. They serve a diverse client base, including corporations, health insurance providers, hospitals and healthcare systems, financial service companies, and individual patients. The Teladoc, Livongo, and BetterHelp brands fall under their purview. Founded in 2002, the company, which operated as Teladoc, Inc. until its renaming in August 2018, is based in Purchase, New York.
4LL Company Deck
4LL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but balanced picture: clear strength and margin expansion in Integrated Care, meaningful product and AI-driven innovation (Teladoc 1 and Pulse), strong liquidity and disciplined cost actions. Offsetting these positives were material near-term challenges in BetterHelp as the business transitions from cash-pay to an insurance/in-network model — accelerated declines in cash-pay users, provider capacity constraints that limited insurance conversion, and a downward revision to consolidated revenue guidance. Management has taken decisive actions (national insurance rollout, provider recruitment/activation initiatives, lower ad spend) to address the issues, but execution risk and timing remain. Overall, the results show operational progress in core businesses and constructive steps to fix the BetterHelp transition, balanced by meaningful short-term revenue pressure and uncertainty in that segment.View all CH:4LL earnings summaries4LL Revenue Breakdown
56.44% Teladoc Health Integrated Care
43.56% BetterHelp
4LL Stock 12 Month Forecast
Average Price Target
CHF6.37
▲(22.24% Upside)